Abstract
BACKGROUND: The use of induction immunosuppression agents has improved kidney transplant outcomes, but selecting the optimal agent remains a point of debate. AIM: To compare the long-term outcomes of kidney transplant recipients receiving alemtuzumab vs basiliximab induction, focusing on graft function, acute rejection, infection, malignancy, post-transplant glomerulonephritis, and survival, using a propensity score matched cohort design. METHODS: Kidney transplant recipients who received alemtuzumab or basiliximab induction from 2014 to 2019 across two nephrology centres in Northwest England were evaluated. Propensity score matching at a 1:1.5 ratio ensured comparability between cohorts. Baseline characteristics, immunosuppression regimens, and outcomes were analyzed. Linear, binary logistics and Cox proportional hazard regression models. RESULTS: A total of 436 recipients were included, with a median follow-up of 5.2 years. The matched cohort (n = 262) had a mean age of 51.1 ± 13.5 years; 39% were female and 92% were white. There was no significant difference in the cumulative incidence of acute rejection [odds ratio (OR) = 2.10; 95%CI: 0.9-4.9; P = 0.110]. Compared with basiliximab, alemtuzumab was associated with lower estimated glomerular filtration rate at 12 months (-6.6 mL/minute/1.73 m(2); 95%CI: -10.5 to -2.7; P < 0.001) and higher risks of cytomegalovirus viremia (OR = 3.2; 95%CI: 1.6-6.5; P < 0.001), BK viremia (OR = 2.4; 95%CI: 1.1-5.5; P = 0.02), post-transplant malignancy (OR = 6.2; 95%CI: 1.6-29.9; P = 0.013), and death-censored graft loss (hazard ratio = 3.6; 95%CI: 1.2-11.4; P = 0.03). No significant differences were observed in post-transplant glomerulonephritis or recipient mortality. CONCLUSION: In this propensity score-matched analysis, alemtuzumab induction was associated with lower graft function at 12 months and higher risks of viral infection, post-transplant malignancy, and graft loss compared with basiliximab. These findings highlight the need for further studies to confirm the long-term safety and effectiveness of alemtuzumab in kidney transplantation.